AMX-883
Amphista Therapeutics announced AMX-883, an oral degrader that recruits the DCAF16 E3 ligase to eliminate the epigenetic reader BRD9. The preclinical program demonstrates selective BRD9 degradation in acute myeloid leukemia (AML) cell models, leveraging a previously identified BRD9 binder for potency and pharmacokinetic optimization. AMX-883 is positioned as a first‑in‑class, orally bioavailable molecular‑glue candidate aimed at addressing the unmet need for targeted AML therapies. The company targets an IND filing within the next 12 months.
A Marine-Inspired Sunscreen Ingredient Made by E. Coli
Researchers at Jiangnan University engineered Escherichia coli to biosynthesize the marine UV‑protective molecule gadusol, achieving a 93‑fold yield increase to 4.2 g per litre. The bacterially produced gadusol demonstrated strong UV‑blocking and antioxidant properties comparable to vitamin C in early tests. By...
Revvity Receives FDA Clearance for Total Testosterone Assay Enabling Comprehensive Automated Testosterone Testing Solution
Revvity, via its Immunodiagnostic Systems unit, secured FDA clearance for a Total Testosterone chemiluminescence immunoassay (ChLIA). The new assay joins FDA‑cleared free testosterone and SHBG tests, creating the only single‑platform, fully automated testosterone testing suite. The portfolio targets hypogonadism diagnosis...
Charles River Laboratories and MEDIPOST Sign Non-Exclusive MOU to Advance GMP Testing Solutions
Charles River Laboratories and South Korean biotech MEDIPOST have signed a non‑exclusive memorandum of understanding to provide GMP‑compliant testing and regulatory support for MEDIPOST’s cell‑therapy pipeline. The collaboration will initially focus on the Asia‑Pacific and North American markets, with the...
Enveric Biosciences Expands IP Portfolio with New U.S. Patent Issued for Methods of Treating Psychiatric Disorders
Enveric Biosciences announced the issuance of U.S. Patent No. 12,605,361 covering its carboxylated psilocybin‑derived EVM301 series for treating psychiatric disorders. The new patent expands the company’s intellectual‑property moat by protecting method claims that build on its earlier patent (No. 11,752,130). Enveric is...
Catalent and Elpida Therapeutics Enter Strategic Partnership for Late-Phase AAV Manufacturing
Elpida Therapeutics and contract manufacturer Catalent have entered a strategic partnership to handle late‑phase manufacturing of Elpida’s lead AAV9 gene therapy for Spastic Paraplegia Type 50 (SPG50). Catalent will also receive exclusive rights to produce Elpida’s other adeno‑associated virus (AAV) programs,...
AI Generates First Complete Models of Proteins in Motion
Scientists at EPFL have unveiled LD‑FPG, an AI‑driven generative framework that creates full‑atom, dynamic models of proteins, moving beyond static predictions like AlphaFold. The system leverages graph neural networks and latent diffusion to generate ensembles that capture side‑chain motions and...
Putting the Boat Out at ASGCT26
Recent oncology‑focused CAR‑T developers are redirecting pipelines toward autoimmune diseases after compelling proof‑of‑concept data in refractory systemic lupus erythematosus and lupus nephritis. The shift includes both autologous and allogeneic cell products as well as emerging in‑vivo RNA‑based therapies delivered via...
Cipla Q4 Profit Falls 54% to $66.8M, Revenue Slips 2.8%, Dividend of ₹13/Share Announced
Cipla Ltd., India's top generic drugmaker, posted a 54% year‑on‑year net profit decline to INR 554.64 crore ($66.8 million) for Q4 FY26, with revenue falling 2.8% to INR 6,541.20 crore ($788 million). The board recommended a final dividend of ₹13 per share,...
Fate Therapeutics Reports First Quarter 2026 Financial Results and Business Updates
Fate Therapeutics reported Q1 2026 results, highlighting a cash balance of $174.8 million that funds operations into 2028. The company announced the upcoming start of the Phase 2 RECLAIM‑LN trial of its off‑the‑shelf CAR‑T product FT819 in lupus nephritis, targeting about 53 patients...
Gene and Cell Therapies Surge: Over 2,000 Projects in 2026
This excellent @Citeline 📊👇shows the exponential rise in the Gene & Cell Therapy field over the past 30 years. 2026 continues show strength with 2,115 Gene Therapies currently being developed to cure genetic diseases & 2,610 Cell therapies in different...
Molecular Grappling Hooks Improve Cancer Drug Targeting and Effectiveness
Scientists have engineered restricted interaction peptides (RIPs) that act as molecular grappling hooks, anchoring anticancer drugs to tumor cell membranes after activation by fibroblast activation protein. In mouse models, a RIP‑linked monomethyl auristatin E payload shrank tumors more effectively and with...
World’s First Human Cervix Chips Among Lush Prize 2026 Winners
The Lush Prize 2026 awarded funding to breakthrough animal‑free organ‑on‑chip technologies. Dr. Zohreh Izadifar of Harvard’s Wyss Institute received roughly $64,000 to develop a human cervix chip that uses electrical sensors to monitor vaginal and cervical cell responses without animal...
Inside the Race to Develop a Test for the Rare Andes Hantavirus
Nebraska’s public‑health laboratory at the University of Nebraska Medical Center has rapidly created a PCR diagnostic test for the rare Andes hantavirus, a strain previously seen only in South America. The test, built in under 48 hours, can detect the...
ICR Scientists Map CDK11 Structure and Self‑regulation, Opening New Cancer Drug Pathways
Researchers at the Institute of Cancer Research in London have determined the active structure of the enzyme CDK11 and identified a novel self‑regulatory mechanism. The discovery, published in Nature Communications, could inform the design of next‑generation cancer therapeutics targeting CDK11...
Gene Therapy Virus Implicated in Boy's Tumor, Study Finds
Scientists link boy’s tumor to gene therapy viruses, in rare finding https://t.co/d2jWn0zs9C via @statnews By @Jasonmmast
New mRNA‑nanoparticle Vaccine Boosts Cancer Potency, Durability
An innovation taking mRNA-nanoparticle cancer vaccines to the next level for potency and durability @NatureBiotech https://t.co/6wBToMGgEA
Novo Nordisk Data Shows Oral Semaglutide Delivers Significant Weight Loss in Phase 3 Trial
Novo Nordisk presented sub‑analyses of the phase 3 OASIS 4 trial at ECO2026, showing that oral semaglutide 25 mg tablets deliver substantial weight loss and functional gains for adults with obesity. Early responders—28.8% of participants—lost at least 10% of body weight by week 16...
Isomorphic Labs Raises $2.1 B Series B to Scale AI Drug‑Design Engine
Isomorphic Labs closed a $2.1 billion Series B financing round led by Thrive Capital, with participation from Alphabet, GV, Temasek, CapitalG and the UK Sovereign AI Fund. The capital will be used to scale its IsoDDE AI engine, expand hiring worldwide,...
SELLAS Life Sciences Posts $8.4M Q1 Loss, Nears Pivotal AML Trial Readout
SELLAS Life Sciences Group posted a wider first‑quarter loss of $8.4 million as it closed in on the final readout of its REGAL Phase 3 trial in acute myeloid leukemia (AML). The company said 78 of the 80 required events have occurred,...
A Plan to Make Drugs in Orbit Is Going Commercial
Varda Space Industries has secured United Therapeutics as its first commercial partner to test drug manufacturing in orbit. The collaboration will send United's pulmonary‑arterial hypertension medicines to microgravity to grow novel crystal forms that could improve stability and efficacy. Varda...
This $250 Million Startup Tracks How Cancer Reacts To Treatment In Real Time
NVision Quantum Technologies announced a $55 million financing round, including $38 million led by diagnostics giant Abbott, to commercialize its metabolic MRI platform that amplifies sugar signals 10,000‑fold for real‑time tumor monitoring. The German‑based startup, valued at over $250 million, plans to roll...
Bond Pet Foods Gets US FDA Nod for Yeast-Brewed Lamb Protein Created with Hill’s Pet Nutrition
Bond Pet Foods and Hill’s Pet Nutrition have secured a Letter of No Objection from the U.S. FDA’s Center for Veterinary Medicine, clearing the way to sell a yeast‑brewed lamb protein in dog food. The ingredient, produced via precision fermentation,...
Boy’s Brain Tumor Tied to Gene Therapy
A 13‑month‑old boy with Hurler syndrome received an in‑vivo AAV‑IDUA gene therapy that later caused a brain tumor when the viral DNA integrated into his genome. The tumor was safely removed and the child remains cognitively advanced, but the case...
Anteris Technologies Global Starts US PARADIGM Trial Enrolment
Anteris Technologies Global announced the start of U.S. patient enrollment in its pivotal PARADIGM trial for the DurAVR transcatheter heart valve. The company raised $320 million in January, including a $230 million public offering and a $90 million private placement with Medtronic, boosting...
Latest TechBio News
A wave of AI‑driven partnerships and funding rounds is reshaping drug discovery, from Insilico Medicine’s collaboration with Ribo on automated oligonucleotide research to LenioBio‑Twist’s 24‑hour cell‑free protein platform. AstraZeneca deepened its Immunai alliance, while Simulations Plus joined forces with NVIDIA...
What Success Can Look Like, Darn It
Vepdegestrant, marketed as Veppanu, became the first FDA‑approved bifunctional degrader, a new PROTAC‑type therapy that eliminates target proteins. A Phase III trial showed it works but delivered no clear efficacy advantage over the existing degrader fulvestrant. Pfizer and Arvinas have now...
ATyr Pharma Charts New Phase 3 Path for Efzofitimod After FDA Type C Meeting
aTyr Pharma announced it will submit an IND in June 2026 for a fresh Phase 3 study of efzofitimod in pulmonary sarcoidosis, prioritizing forced vital capacity as the primary endpoint. The move follows FDA Type C meeting feedback and includes...
Actuate Therapeutics Secures FDA IND Clearance for First Oral Elraglusib Tablet
Actuate Therapeutics announced FDA clearance of an Investigational New Drug application for an oral tablet of elraglusib, paving the way for a Phase 1/2 study in solid‑tumor patients. The move follows positive Phase 2 data in metastatic pancreatic cancer and...
AI-Powered Handheld Microscope May Improve Early Cancer Detection
Researchers at Rice University and MD Anderson have created PrecisionView, a pen‑sized handheld endomicroscope that combines AI‑designed optics with deep‑learning reconstruction. The device delivers cellular‑level resolution across a field of view five times larger and a depth of field eight...
Coya Therapeutics Secures FDA Fast Track for ALS Drug COYA 302
Coya Therapeutics announced that the U.S. Food and Drug Administration granted Fast Track status to its experimental ALS therapy, COYA 302. The designation promises accelerated review and closer agency interaction, underscoring the urgent need for new treatments in amyotrophic lateral sclerosis.
Servier's Emi-Le Secures FDA Breakthrough Therapy Designation for Rare Salivary‑Gland Cancer
Servier announced that the U.S. FDA granted breakthrough therapy designation to its investigational antibody‑drug conjugate Emi-Le for locally advanced, recurrent or metastatic adenoid cystic carcinoma. The designation accelerates the Phase 1 program and underscores the promise of B7‑H4‑directed ADCs in...
Implantable Cytokine Factories Show Promise Against Advanced Ovarian Cancer
Researchers at Rice University and MD Anderson reported first‑in‑human results for AVB‑001, an implantable cell capsule that continuously secretes interleukin‑2 within the peritoneal cavity of patients with high‑grade serous ovarian cancer. In a Phase I dose‑escalation study of 14 platinum‑resistant...
AI Enables Creation of Minimalist Organism Under 20 Amino Acids
Scientists just made the first ever observed organism with fewer than 20 amino acids in its make-up, and it was made possible by AI. https://t.co/ZCkvq4Rdas
FDA Approves Ocrevus for Children 10+ with Relapsing‑Remitting MS
The U.S. Food and Drug Administration has approved Genentech's Ocrevus (ocrelizumab) for pediatric patients aged 10 and up with relapsing‑remitting multiple sclerosis. The decision follows the phase‑3 OPERETTA 2 trial, which showed a 48% lower annualized relapse rate versus fingolimod. The...
Isomorphic Labs Secures $2.1 B Series B to Scale AI Drug Design Engine
Isomorphic Labs announced a $2.1 billion Series B funding round led by Thrive Capital, with participation from Alphabet, GV, Temasek, CapitalG and the UK Sovereign AI Fund. The capital will expand its IsoDDE AI engine, accelerate its therapeutic pipeline and fund...
Addition Therapeutics Shows Durable Gene‑Editing Proof‑of‑Concept at ASGCT
Addition Therapeutics unveiled preclinical non‑human primate data confirming durable protein expression from its all‑RNA, LNP‑based PRINT platform at the American Society of Gene & Cell Therapy meeting in Boston. The results, spanning obesity, Fabry disease, HIV and ocular indications, could...
Talphera Inc (TLPH) Q1 2026 Earnings Call Transcript
Talphera reported a $21.1 million cash balance and closed a $4.1 million financing tranche, with two additional conditional tranches of $16 million tied to study milestones. The nephro CRRT trial has surpassed the 50% enrollment target and is on track for full enrollment...
Allogene Therapeutics Inc (ALLO) Q1 2026 Earnings Call Transcript
Allogene Therapeutics reported interim data from its pivotal ALPHA-3 trial, showing SemiCell achieved a 58.3% MRD clearance rate versus 16.7% in the observation arm—a 41.6% absolute improvement—alongside a near‑98% median ctDNA reduction. The safety profile was clean, with no cases...
Beyondspring Inc (BYSI) Q1 2026 Earnings Call Transcript
BeyondSpring Inc. reported that its lead asset plinabulin received FDA priority review with a PDUFA decision deadline of November 30, 2021. The company completed enrollment of 559 patients in the global Phase 3 DUBLIN‑3 trial for second‑line non‑small cell lung cancer...
Humacyte Inc (HUMA) Q1 2026 Earnings Call Transcript
Humacyte reported a sharp rise in Symvess product revenue to $703,000 in Q1 2026, driven by expanding hospital approvals and its first sale to U.S. military facilities after ECAT listing. The company secured 25 Value Analysis Committee approvals covering 92...
PolyPid Ltd (PYPD) Q1 2026 Earnings Call Transcript
PolyPid announced that its D‑PLEX100 product achieved primary and all key secondary endpoints in the SHIELD II Phase III trial, confirming a meaningful reduction in surgical site infections. The FDA provided written feedback endorsing a rolling new drug application, with...
Omeros Corp (OMER) Q1 2026 Earnings Call Transcript
Omeros Corp reported Q1 2020 results, highlighting progress on its lead antibody narsoplimab as it nears completion of a rolling biologics license application (BLA) with breakthrough therapy designation and anticipated priority review. The company also detailed its Omidria cataract‑surgery product,...
Sub‑minute, Low‑power Device Prevents Kidney Ice Formation
getting through the danger zone for ice formation in under a minute, with a device that only draws a few kW (work done on a pig kidney, same scale as a human kidney) https://t.co/bQooglhqBU
Weight Loss Maintained Seven Times More Effectively with Continued Maximum Dose of Tirzepatide, Study Finds
A Phase 3b trial presented at ECO 2026 showed that continuing tirzepatide at the maximum tolerated dose (10 mg or 15 mg) after an initial 60‑week weight‑loss phase preserved a 21.9% reduction from baseline after a further 52 weeks, compared with only 9.9% in the...
Lilly Points to Low-Dose Zepbound and Foundayo as Weight Loss Maintenance Options
Eli Lilly’s phase‑III trial indicates that a reduced dose of its obesity injectable Zepbound can sustain weight loss while improving safety and lowering costs. The study also highlighted Foundayo, an oral GLP‑1 candidate, as a viable maintenance therapy for patients preferring...
Physionic Podcast Videos and Summaries / Transcripts
A 2023 meta‑analysis of 29,913 patients shows that pure EPA, administered as icosapent ethyl, significantly reduces myocardial infarction, cardiovascular death and all‑cause mortality. The REDUCE‑IT trial, using 4 g daily of prescription EPA, delivered a 25 % relative risk reduction and a...
Personalized DNA Vaccine Doubles Glioblastoma Survival Rates
A phase‑1 trial of Geneos Therapeutics' personalized DNA vaccine GNOS‑PV01 showed it was safe and generated robust immune responses in newly diagnosed glioblastoma patients. The vaccine, which encodes up to 40 patient‑specific neoantigens, more than doubled 12‑month overall survival to...
Slowing Parkinson’s by Blocking a Key Protein
Researchers at the University of Pennsylvania have pinpointed glycoprotein nonmetastatic melanoma B (GPNMB) as a key driver of alpha‑synuclein spread in Parkinson’s disease. In pre‑clinical models, monoclonal antibodies that block GPNMB halted the neuron‑to‑neuron transmission of toxic protein clumps. Analysis...
GLP-1 Drugs Dramatically Reduce “Food Noise” In Weight Loss
Researchers presented data at the European Congress on Obesity showing that adding GLP‑1 receptor agonist drugs to a digital behavioral weight‑management program dramatically lowers "food noise," the intrusive thoughts about food that hinder healthy choices. In a month‑long trial, participants...